Prothena Corporation plc - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
PRTA Nasdaq 2830 www.prothena.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Prothena Corporation plc

Fortrea Holdings Inc. (FTRE) Moves 5.5% Higher: Will This Strength Last? - Jan 7th, 2026 6:06 am
How Are Partnered Pipelines Rewriting The Prothena (PRTA) Narrative And Price Target Outlook - Jan 5th, 2026 2:08 pm
We Think Prothena (NASDAQ:PRTA) Can Afford To Drive Business Growth - Jan 2nd, 2026 10:03 am
Prothena Announces Board of Directors Update - Dec 12th, 2025 2:05 pm
How the Narrative Surrounding Prothena Is Changing After New Pipeline and Valuation Updates - Dec 6th, 2025 9:07 am
Why The Narrative Around Prothena Is Shifting After Analysts Raise Targets and Clinical Updates - Nov 22nd, 2025 3:08 am
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025 - Nov 19th, 2025 2:05 pm
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA - Nov 11th, 2025 7:00 am
Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus - Nov 7th, 2025 8:32 am
Why The Narrative Around Prothena Is Shifting Amid Analyst Optimism and New Developments - Nov 7th, 2025 4:14 am
Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates - Nov 6th, 2025 3:45 pm
Prothena: Q3 Earnings Snapshot - Nov 6th, 2025 2:46 pm
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights - Nov 6th, 2025 2:05 pm
Prothena to Report Third Quarter 2025 Financial Results on November 6 - Oct 30th, 2025 2:05 pm
Prothena Corporation plc (PRTA): A Bull Case Theory - Oct 22nd, 2025 1:33 pm
One Prothena Insider Raised Their Stake In The Previous Year - Oct 16th, 2025 5:10 am
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease - Oct 1st, 2025 2:45 pm
Prothena Down 40% Year to Date: What Lies Ahead for the Stock? - Sep 11th, 2025 8:01 am
Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue? - Sep 3rd, 2025 9:30 am
Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference - Aug 28th, 2025 2:05 pm